Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor.

ABSTRACT:

Background

The BRAF inhibitor vemurafenib (PLX) has shown promise in treating metastatic melanoma, but most patients develop resistance to treatment after 6 mo. We identified a transmembrane protein, extracellular matrix metalloproteinase inducer (EMMPRIN) as a cell surface receptor highly expressed by PLX-resistant melanoma. Using an S100A9 ligand, we created an EMMPRIN targeted probe and liposome that binds to melanoma cells in vivo, thus designing a novel drug delivery vehicle.

Methods

PLX-resistant cells were established through continuous treatment with PLX-4032 over the course of 1 y. Both PLX-resistant and sensitive melanoma cell lines were evaluated for the expression of unique cell surface proteins, which identified EMMPRIN as an overexpressed protein in PLX0-resist

SUBMITTER: Zeiderman MR 

PROVIDER: S-EPMC4576881 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature